AYTU BIOPHARMA, INC Payments to Acquire Other Productive Assets
AYTU BIOPHARMA, INC (AYTU) reported Payments to Acquire Other Productive Assets of $5.85 million for the 12-month period ending 2020-06-30, per its 10-K filed 2020-10-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherProductiveAssets · last filed 2020-10-06
- AYTU BIOPHARMA, INC payments to acquire other productive assets for the quarter ending 2020-06-30 was $0.00.
- AYTU BIOPHARMA, INC payments to acquire other productive assets for the quarter ending 2020-03-31 was $1.35M.
- AYTU BIOPHARMA, INC payments to acquire other productive assets for the quarter ending 2019-12-31 was $4.50M, a 800.00% increase year-over-year.
- AYTU BIOPHARMA, INC payments to acquire other productive assets for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC payments to acquire other productive assets for fiscal 2020 was $5.85M, a 1070.00% increase from fiscal 2019.
- AYTU BIOPHARMA, INC payments to acquire other productive assets for fiscal 2019 was $500.00K, a 25.00% increase from fiscal 2018.
- AYTU BIOPHARMA, INC payments to acquire other productive assets for fiscal 2018 was $400.00K, a 46.67% decline from fiscal 2017.
- AYTU BIOPHARMA, INC payments to acquire other productive assets for fiscal 2017 was $750.00K, a 27.88% decline from fiscal 2016.
| Period end | Payments to Acquire Other Productive Assets 3 month | Payments to Acquire Other Productive Assets 6 month | Payments to Acquire Other Productive Assets 9 month | Payments to Acquire Other Productive Assets 12 month |
|---|---|---|---|---|
| 2020-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $1.35M derived: sum of 2 quarters · filed 2020-10-06 | $5.85M derived: sum of 3 quarters · filed 2020-10-06 | $5.85M 10-K · filed 2020-10-06 |
| 2020-03-31 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $5.85M derived: sum of 2 quarters · filed 2020-05-15 | $5.85M 10-Q · filed 2020-05-15 | $5.85M derived: sum of 4 quarters · filed 2020-10-06 |
| 2019-12-31 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $4.50M 10-Q · filed 2020-02-14 | $4.50M derived: sum of 3 quarters · filed 2020-10-06 | $4.20M derived: sum of 4 quarters · filed 2020-10-06 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2020-10-06 | -$300.00K derived: sum of 3 quarters · filed 2020-10-06 | $200.00K derived: sum of 4 quarters · filed 2020-10-06 |
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | -$300.00K derived: sum of 2 quarters · filed 2020-10-06 | $200.00K derived: sum of 3 quarters · filed 2020-10-06 | $500.00K 10-K · filed 2020-10-06 |
| 2019-03-31 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15 | $200.00K derived: sum of 2 quarters · filed 2020-05-15 | $500.00K 10-Q · filed 2020-05-15 | $900.00K derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $800.00K 10-Q · filed 2020-02-14 | $1.20M derived: sum of 3 quarters · filed 2020-02-14 | |
| 2018-09-30 | $300.00K 10-Q · filed 2019-11-14 | $700.00K derived: sum of 2 quarters · filed 2019-11-14 | ||
| 2018-06-30 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $400.00K 10-K · filed 2019-09-26 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-14 | |||
| 2017-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $0.00 derived: sum of 2 quarters · filed 2018-09-06 | $250.00K derived: sum of 3 quarters · filed 2018-09-06 | $750.00K 10-K · filed 2018-09-06 |
| 2017-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14 | $250.00K derived: sum of 2 quarters · filed 2018-05-14 | $750.00K 10-Q · filed 2018-05-14 | $1.25M derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08 | $750.00K 10-Q · filed 2018-02-08 | $1.25M derived: sum of 3 quarters · filed 2018-02-08 | $1.25M derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-09-30 | $500.00K 10-Q · filed 2017-11-09 | $1.00M derived: sum of 2 quarters · filed 2017-11-09 | $1.00M derived: sum of 3 quarters · filed 2017-11-09 | $1.54M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31 | $500.00K derived: sum of 2 quarters · filed 2017-08-31 | $1.04M derived: sum of 3 quarters · filed 2017-08-31 | $1.04M 10-K · filed 2017-08-31 |
| 2016-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | $540.00K derived: sum of 2 quarters · filed 2017-05-11 | $540.00K 10-Q · filed 2017-05-11 | |
| 2015-12-31 | $540.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $540.00K 10-Q · filed 2017-02-09 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |